Description
BG-68501 is an experimental drug currently being studied in clinical trials. It is being investigated as a potential treatment for advanced solid tumors, including breast cancer. In the context of colorectal cancer, the provided data indicates it is being studied in Phase 1 trials, primarily to determine its safety and how it is processed by the body (pharmacokinetics). The trials may also look at preliminary signs of effectiveness (antitumor activity). It is being tested alone (monotherapy) and in combination with other drugs like fulvestrant and BGB-43395. The specific role of BG-68501 in colorectal cancer treatment is still under investigation.
Mechanism of Action
BG-68501 is classified as a cyclin-dependent kinase-2 inhibitor (CDK2i). Cyclin-dependent kinases (CDKs) are proteins that help regulate the cell cycle, which is the process by which cells grow and divide. By inhibiting CDK2, BG-68501 aims to interfere with the cell cycle, potentially slowing down or stopping the growth of cancer cells. The specific mechanism and effectiveness in different types of cancer, including colorectal cancer, are still being studied.
Side Effects
Not all side effects are listed. Side effects vary by individual. Always consult your oncologist.